Universe Pharmaceuticals has successfully completed its self-underwritten public offering on July 15, 2024, raising $25 million before expenses. The offering consisted of 20 million ordinary shares priced at $1.25 per share, with a par value of $0.01875 per share.The company, headquartered in Jiangxi, China, executed this capital raising initiative through a self-managed offering process, demonstrating direct market engagement. The funds were raised before deducting offering-related expenses, indicating potential net proceeds below the gross amount.

Universe Pharmaceuticals has successfully completed its self-underwritten public offering on July 15, 2024, raising $25 million before expenses. The offering consisted of 20 million ordinary shares priced at $1.25 per share, with a par value of $0.01875 per share.The company, headquartered in Jiangxi, China, executed this capital raising initiative through a self-managed offering process, demonstrating direct market engagement. The funds were raised before deducting offering-related expenses, indicating potential net proceeds below the gross amount.